Dilip Shanghvi
Indian businessman; founder and executive chairman of Sun Pharmaceutical Industries
| Dilip Shanghvi
| |
|---|---|
| Image | .jpg) Dilip Shanghvi |
| Born | 1 October 1955 |
| Nationality | India |
| Occupation | Businessman |
| Known for | Founder and executive chairman of Sun Pharmaceutical Industries |
| Children | 2 |
| Education | University of Calcutta (Forbes) |
Dilip Shantilal Shanghvi (born 1 October 1955) is an Indian businessman. He founded Sun Pharmaceutical Industries in 1983 and has been its executive chairman since 1 September 2025, when he handed the managing director's role to Kirti Ganorkar.[1][2] He received the Padma Shri in 2016.[3] On 20 October 2026 the Forbes Real-Time Billionaires list ranked Dilip Shanghvi 100th in the world, with an estimated net worth of US$24.78 billion; Forbes lists the source of wealth as Pharmaceuticals.[1][4] In the annual World's Billionaires list published in 2026, Forbes had ranked Dilip Shanghvi 100th, at US$25.6 billion.[5]
Early life and education
Forbes says Shanghvi is the son of a pharmaceuticals distributor and lists a bachelor's degree from Calcutta University.[1]
Career
According to Forbes, Shanghvi borrowed US$200 from his father to start Sun Pharmaceutical Industries in 1983, initially making psychiatric drugs. Forbes says he grew the company through acquisitions, the largest being the US$4 billion purchase of Ranbaxy Laboratories in 2014, and that Sun bought Concert Pharmaceuticals in 2023 and Checkpoint Therapeutics in May 2025.[1]
At Sun's annual general meeting on 31 July 2025, Shanghvi reported that FY2025 revenue had risen 9.0% to ₹520 billion, that global specialty revenue had grown 17.1% to US$1,216 million, and that the workforce exceeded 43,000. He said the acquisition of Taro had been completed, making it a wholly owned subsidiary.[6] Sun announced on 13 June 2025 that Kirti Ganorkar would succeed him as managing director from 1 September 2025. Shanghvi would continue to chair the board as executive chairman, concentrating on specialty medicines and long-term strategy. His son Aalok Shanghvi, a whole-time director and chief operating officer, took on added responsibility for the North America business.[2]
SEBI settlement (2021)
In May 2020 SEBI issued show-cause notices to Sun Pharma, its whole-time directors and certain officers. They followed an investigation prompted by two whistleblower complaints and concerned related-party compliance under SEBI's listing regulations.[7] According to PTI, the complaints alleged that funds had been diverted through Sun's sole Indian distributor, Aditya Medisales.[8] On 11 February 2021 the proceedings were settled without admitting or denying the findings, with total settlement charges of ₹2,92,10,250 (about ₹2.92 crore).[7] PTI reported that Shanghvi's share was ₹62.35 lakh.[8]
Wealth
Forbes gives pharmaceuticals as the source of his wealth. It says Sun is India's most valuable listed pharmaceutical company and earns about two-thirds of its revenue overseas.[1][4]
Wealth history
Forbes has included this entry in its annual World's Billionaires list in 22 of the editions from 2001 to 2026 checked for this profile, starting with 2005. The table gives the rank and estimated net worth in each annual list.[5][1]
| Year | World's Billionaires rank | Net worth (US$ bn) |
|---|---|---|
| 2005 | 437 | 1.5 |
| 2006 | 317 | 2.4 |
| 2007 | 279 | 3.1 |
| 2008 | 260 | 4.0 |
| 2009 | 205 | 3.0 |
| 2010 | 173 | 4.6 |
| 2011 | 159 | 6.1 |
| 2012 | 124 | 7.4 |
| 2013 | 116 | 9.4 |
| 2014 | 82 | 12.8 |
| 2015 | 44 | 20.0 |
| 2016 | 44 | 16.7 |
| 2017 | 84 | 13.7 |
| 2018 | 115 | 12.8 |
| 2019 | 191 | 7.6 |
| 2020 | 253 | 6.1 |
| 2021 | 203 | 10.9 |
| 2022 | 115 | 15.6 |
| 2023 | 112 | 15.6 |
| 2024 | 69 | 26.7 |
| 2025 | 79 | 24.9 |
| 2026 | 100 | 25.6 |
Honours
Shanghvi was awarded the Padma Shri for trade and industry in the 2016 Padma Awards (Gazette notification No. 30-Pres/2016 of 28 March 2016).[3]
Political activity
No elected offices, party donations or lobbying registrations were found for Shanghvi personally in the sources checked.
International and political links
This section uses the same ten headings for every profile in this series. Only specific, sourced actions are included; company-level and foundation-level actions are labelled as such. Where nothing was found, the entry reads "No documented involvement found in sources checked."
Israel (investments, operations, donations, contracts, statements)
No documented involvement found in sources checked.
Zionist or pro-Israel organisations and lobbying groups
No documented involvement found in sources checked.
Jewish communal charities
No documented involvement found in sources checked.
Gulf states
No documented involvement found in sources checked.
China
No documented involvement found in sources checked.
Russia
No documented involvement found in sources checked.
India
Indian national. Founder of what Forbes calls India's most valuable listed pharmaceutical company; Padma Shri, 2016.[1][3]
Palestinian or Arab causes
No documented involvement found in sources checked.
Home government
His home government is India's. The securities regulator, SEBI, settled related-party disclosure proceedings against Sun Pharma, Shanghvi and other officers in 2021.[7][8]
Other international links
United States (company-level): US sales were ₹162 billion in FY2025, 31% of the total, and in 2025 Sun acquired the US company Checkpoint Therapeutics; its North America business reports to Aalok Shanghvi.[6][2][1]
See also
External links
Notes
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Forbes, Forbes profile record for Dilip Shanghvi (Forbes data feed behind forbes.com/profile/dilip-shanghvi/) Forbes, live record, read 21 October 2026, accessed 21 October 2026.
- ↑ 2.0 2.1 2.2 Sun Pharmaceutical Industries Limited, Sun Pharma appoints Kirti Ganorkar as the Managing Director; Dilip Shanghvi to continue as the Executive Chairman of the Board (press release) Sun Pharma, 13 June 2025, accessed 21 October 2026.
- ↑ 3.0 3.1 3.2 President's Secretariat, Government of India, Notification No. 30-Pres/2016 (Padma Awards 2016) The Gazette of India: Extraordinary, 28 March 2016, accessed 21 October 2026.
- ↑ 4.0 4.1 Forbes, Forbes Real-Time Billionaires data feed Forbes, live; downloaded 20 October 2026 11:51 UTC, accessed 20 October 2026.
- ↑ 5.0 5.1 Forbes, Forbes World's Billionaires list data feed, annual editions 2001–2026 (one file per year at this path with the year substituted; all 26 files downloaded and read) Forbes, annual lists; downloaded 20 October 2026, accessed 20 October 2026.
- ↑ 6.0 6.1 Sun Pharmaceutical Industries Limited, Outcome of the 33rd Annual General Meeting (filing to stock exchanges, with chairman's speech) Sun Pharma, 31 July 2025, accessed 21 October 2026.
- ↑ 7.0 7.1 7.2 Sun Pharmaceutical Industries Limited, Conclusion of settlement proceedings with SEBI (filing to NSE and BSE) Sun Pharma, 11 February 2021, accessed 21 October 2026.
- ↑ 8.0 8.1 8.2 PTI, Sun Pharma, officials including Dilip Shanghvi settle case of alleged market norms violation with Sebi The Times of India, 11 February 2021, accessed 21 October 2026.